How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?

Expert Opin Pharmacother. 2020 Feb;21(3):243-245. doi: 10.1080/14656566.2019.1705280. Epub 2020 Jan 3.

Authors

Daniel Neureiter^{1

2}, Christian Mayr^{3

4}, Tobias Kiesslich^{3

4}

Affiliations

¹ Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.
² Cancer Cluster Salzburg, Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria.
³ Department of Internal Medicine I, Paracelsus Medical University, Salzburg, Austria.
⁴ Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.

PMID: 31899989
DOI: 10.1080/14656566.2019.1705280

No abstract available

Keywords: Biliary tract cancer; Chemoresistance; Chemotherapy; Patient-derived xenografts.

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents*
Biliary Tract Neoplasms*
Humans
Standard of Care

Substances

Antineoplastic Agents